Detection of promoter methylation status of suppressor of cytokine signaling 3 (SOCS3) in tissue and plasma from Chinese patients with different hepatic diseases

Wei, Ling; Huang, Yuan; Zhao, Rongzhen; Zhang, Jing; Liu, Qiuying; Liang, Weibo; Ding, Xueqin; Gao, Bo; Li, Bo; Sun, Chengjun; He, Jingjing; Yu, Xiaoqin; Liu, Zhong‐Jian; Sun, Aimin; Qin, Yang

doi:10.1007/s10238-017-0473-2

Cited by 30 publications

(25 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The model further differentiated patients with HCC from those with hepatitis B virus (HBV)/HCV infection and fatty liver disease [115]. Suppressor of cytokine signaling 3 (SOCS3) methylation in both HCC tissue and plasma was also found to be associated with tumor size and differentiation, metastasis, and recurrence, as well as with poorer prognosis [116].…”

Section: Cfdnamentioning

confidence: 99%

Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning?

Mocan

Simão

Castro

et al. 2020

JCM

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) represents the sixth most common cancer worldwide and the third most common cause of cancer-related death. One of the major problems faced by researchers and clinicians in this area is the lack of reliable disease biomarkers, which would allow for an earlier diagnosis, follow-up or prediction of treatment response, among others. In this regard, the “HCC circulome”, defined as the pool of circulating molecules in the bloodstream derived from the primary tumor, represents an appealing target, the so called liquid biopsy. Such molecules encompass circulating tumor proteins, circulating tumor cells (CTCs), extracellular vesicles (EVs), tumor-educated platelets (TEPs), and circulating tumor nucleic acids, namely circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA). In this article, we summarize recent findings highlighting the promising role of liquid biopsies as novel potential biomarkers in HCC, emphasizing on its clinical performance.

show abstract

Section: Cfdnamentioning

confidence: 99%

Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning?

Mocan

Simão

Castro

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…To investigate the methylation status of CpG islands of RASSF1A , p16 , SFRP1 , SOCS3 and LINE1, multiplex MSP was performed in a 25µL-volume reaction system, consisted of 50ng sodium-bisulfite treated DNA, isometric mixture of gene primers 3µL, 2×Master Mix 12.5µL (Qiagen, Germany) and ddH 2 O. The multiplex MSP primer sequences for RASSF1A , p16 , SFRP1 , SOCS3 and LINE1 were described in Table S1 11 , 14 , 20 - 22 . The reaction conditions were listed as follows: denaturation at 95℃ for 15 min, 30 cycles of 94℃ for 30s, annealing for 90s and 72℃ for 90s, with an ultimate extension of 10 min at 72℃.…”

Section: Methodsmentioning

confidence: 99%

Predicting hepatocellular carcinoma development for cirrhosis patients via methylation detection of heparocarcinogenesis-related genes.

et al. 2018

Self Cite

View full text Add to dashboard Cite

Background: Most hepatocellular carcinoma (HCC) patients have undergone a progression from chronic hepatitis, then liver cirrhosis (LC), and finally to carcinoma. The objective of this study was to elucidate risk factors to predict HCC development for cirrhosis patients.Methods: Multiple methylated specific PCR (MSP) was applied to determine methylation status of heparocarcinogenesis-related genes in 396 tissue and plasma specimens and multivariate cox model was used to analyze the relationship between risk variables and HCC development among cirrhosis patients, followed up in a median period of 30 months.Results: Among 105 LC cases, HCC incidence rate at 30 months was 30.48% (32/105), which were statistically associated with patients' age and aberrant methylation of p16, SFRP, and LINE1 (p<0.05). Receiver operating characteristic (ROC) curve showed the overall predictive accuracy reached the highest (90.7%) if the four risk variables were concurrent to predict HCC development. Moreover, along with the growth of age from 0-40, 40-55, to 55-70 years or the increased number of aberrantly-methylated gene from 0-1 to 2-3, the HCC incidence rate of cirrhosis patients rised from 10.00%, 12.28% to 82.14% and 17.44% to 89.47%, separately. Thus, based on combined analysis with diverse age and number of aberrantly-methylated gene, 105 cases were divided into five groups and computed their respective HCC incidecne rate to categorize them into different risk groups. Of note, A significant lifting of HCC incidence rate in the high-risk group (40-55 years coupled with 2-3 aberrantly-methylated genes, 55-70 years coupled with 0-1 aberrantly-methylated gene, 55-70 years coupled with 2-3 aberrantly-methylated genes; n=33) was observed compared with the low-risk group (0-40 years coupled with 0-1 aberrantly-methylated gene, 40-55 years coupled with 0-1 aberrantly-methylated gene; (n=72) (p<0.01).Conclusions: Ultimately, high-risk cirrhosis patients with 55-over years or 2-3 aberrantly-methylated genes should be paid more attention to be regularly screened with HCC development.

show abstract

“…Changes in DNA methylation have been shown to be pivotal in the development of HCC, particularly within the CpG islands of tumour suppressor genes. A number of studies have analysed methylation patterns in HCC tumour resections and reported hypermethylation of p15, CDKN2A (encoding for p16), glutathione S -transferase P1 ( GSTP1 ), Ras association domain family 1A ( RASSF1A ), APC, SOCS1, SOCS3, TIMP3, blood vessel epicardial substance (BVES) and Homeobox A9 (HOXA9) genes and hypomethylation of long interspersed element-1 (LINE-1) repetitive sequence within the tumours 6 29–35. However, the same methylation pattern was detectable in only a subproportion of the reported genes found in cfDNA/ctDNA; for example, hypermethylation of GSTP1 was detected in 50% of the cfDNA, RASSF1A was found in 70%–93% (depending on the study), whereas hypomethylation of LINE-1 was present in 66.7% of cfDNA in the sera of patients with HCC 32 33.…”

Section: Circulating Nucleic Acidsmentioning

confidence: 99%

Liquid biopsy for liver diseases

Mann

Reeves

Feldstein

2018

Gut

View full text Add to dashboard Cite

With the growing number of novel therapeutic approaches for liver diseases, significant research efforts have been devoted to the development of liquid biopsy tools for precision medicine. This can be defined as non-invasive reliable biomarkers that can supplement and eventually replace the invasive liver biopsy for diagnosis, disease stratification and monitoring of response to therapeutic interventions. Similarly, detection of liver cancer at an earlier stage of the disease, potentially susceptible to curative resection, can be critical to improve patient survival. Circulating extracellular vesicles, nucleic acids (DNA and RNA) and tumour cells have emerged as attractive liquid biopsy candidates because they fulfil many of the key characteristics of an ideal biomarker. In this review, we summarise the currently available information regarding these promising and potential transformative tools, as well as the issues still needed to be addressed for adopting various liquid biopsy approaches into clinical practice. These studies may pave the way to the development of a new generation of reliable, mechanism-based disease biomarkers.

show abstract

Detection of promoter methylation status of suppressor of cytokine signaling 3 (SOCS3) in tissue and plasma from Chinese patients with different hepatic diseases

Cited by 30 publications

References 34 publications

Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning?

Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning?

Predicting hepatocellular carcinoma development for cirrhosis patients via methylation detection of heparocarcinogenesis-related genes.

Liquid biopsy for liver diseases

Contact Info

Product

Resources

About